Aug 15 (Reuters) - Bristol-Myers Squibb Co said on Tuesday its combination drug to treat previously untreated patients with advanced or metastatic renal cell carcinoma, a type of kidney cancer, failed to meet one of the main goals of a late-stage trial.
The combination of Bristol-Myers' two top drugs, Opdivo and Yervoy, was not statistically significant in improving progression-free survival in patients, when compared with standard-of-care drug sunitinib.
The treatment, however, met another main goal of the study.
Bristol-Myers shares were down about 2 percent at $56.49 in after-hours trading. (Reporting by Divya Grover in Bengaluru; Editing by Shounak Dasgupta)